SCHEMBL1998314

SCHEMBL1998314

CCn1nc(C(=O)OCc2cccc(C)c2)cc(N)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.44
HPGD P15428 3/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP12 P39900 1/20 0.44
POLB P06746 1/20 0.39
PTGER1 P34995 1/20 0.39
IDO1 P14902 2/20 0.39
ALDH1A1 P00352 3/20 0.38
LMNA P02545 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
ADORA2B P29275 1/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001144 0.89 MAPT (0.45) SMN1; SMN2ALDH1A1LMNAKDM4EMAPT
SCHEMBL1997786 0.88 KMT2A (0.47) SMN1; SMN2HPGDMMP2MMP9MMP12
SCHEMBL1998180 0.87 ALDH1A1 (0.53) SMN1; SMN2HPGDMMP2MMP9MMP12
SCHEMBL1999815 0.85 POLB (0.41) POLBALDH1A1KDM4EMAPTADORA2A
SCHEMBL1996512 0.85 MMP1 (0.49) SMN1; SMN2MMP12PTGER1IDO1MAPT
SCHEMBL1994640 0.82 KDM4E (0.43) SMN1; SMN2HPGDPOLBALDH1A1LMNA
SCHEMBL1999820 0.82 ALDH1A1 (0.42) HPGDPOLBALDH1A1KDM4EMAPT
SCHEMBL1999469 0.81 KMT2A (0.41) SMN1; SMN2HPGDALDH1A1LMNAKDM4E
SCHEMBL1996427 0.81 MMP9 (0.43) SMN1; SMN2MMP2MMP9MMP12ALDH1A1
SCHEMBL1999165 0.80 GABRP (0.38) ALDH1A1LMNAMAPTADORA2BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960383-B2 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL SA (ES) 2011-06-14 US disclosed
EP-1758869-B1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL SA (ES) 2010-12-22 EP disclosed
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors ALMIRALL PRODESFARMA, SA (ES) 2008-11-13 US disclosed
EP-1758869-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2007-03-07 EP disclosed
WO-2005123692-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors PDE12, PDE4A, PDE4B SMN1; SMN2 4021/4885HPGD 138/4885MMP2 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.